Jeena Sikho Lifecare Limited (JSLL) Fair Value & Analysis
Healthcare · IN · Market cap ₹71.4B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price −16.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹458.81 – ₹834.42 · fair‑value band ₹267.72 – ₹996.04 · the ₹574.40 price screens above the ₹362.03 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jeena Sikho Lifecare Limited (JSLL) currently trades at ₹574.40, while our model-based Fair Value estimate is ₹362.03 — implying the stock looks roughly 37.0% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jeena Sikho Lifecare Limited generated revenue of ₹8.0B at a net margin of 27.7%. Revenue grew 54.8% year over year. It earns a return on equity of 59.9%. Net debt stands at ₹52.4M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Jeena Sikho Lifecare Limited trades in ayurvedic medicines in India. The company offers ayurvedic products under the Shuddhi brand name. It also provides services, including in-patient, out-patient, 72 hours health camps, Panchakarma therapies, dietary support and nutrition guidance, home-based healthcare services, and healthcare support centre services. In addition, the company operates clinics under the Shuddhi Ayurveda, Shuddhi Clinics, Hospital & Institution of Integrated Medical Sciences, Shuddhi Wellness Clinics & Hospital, Shuddhi Ayurveda Panchakarma Hospital, and Shuddhi Panchakarma Day Care Clinic names. Jeena Sikho Lifecare Limited was founded in 2009 and is headquartered in Zirakpur, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jeena Sikho Lifecare Limited reported revenue of ₹8.0B in FY2026 versus ₹1.5B in FY2022, a compound +52.9%/yr. Reported net income was ₹2.2B in FY2026, compounding +110.8%/yr from FY2022.
Is JSLL fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jeena Sikho Lifecare Limited (JSLL) undervalued?
What is the fair value of JSLL?
What is the quality score of JSLL?
What is the revenue of Jeena Sikho Lifecare Limited (JSLL)?
What is the net profit margin of JSLL?
Does Jeena Sikho Lifecare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.